Wells Fargo Sticks to Their Buy Rating for Medtronic (MDT)
Wells Fargo Maintains Medtronic(MDT.US) With Buy Rating, Announces Target Price $105
Buy Rating Affirmed for Medtronic on Recent FDA Approvals and Competitive Market Positioning
DexCom Reaches a Multi-year Low as Downgrades Follow Guidance Cut
Truist Securities Maintains Hold on Medtronic, Lowers Price Target to $85
Medtronic Analyst Ratings
Truist Trims Price Target on Medtronic to $85 From $88, Keeps Hold Rating
Medtronic's Stable Outlook and Growth Prospects Reinforce Buy Rating
Mizuho Securities Cuts Price Target on Medtronic to $95 From $98
Medtronic Analyst Ratings
Goldman Sachs Adjusts Price Target on Medtronic to $77 From $83
Medtronic Analyst Ratings
Daiwa Securities Adjusts Price Target on Medtronic to $92 From $100
Medtronic Analyst Ratings
RBC Capital Keeps Their Hold Rating on Medtronic (MDT)
Truist Securities Adjusts Price Target on Medtronic to $88 From $90, Keeps Hold Rating
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Medtronic (MDT) and Cytokinetics (CYTK)
Medtronic Analyst Ratings
Medtronic Poised for Growth: A Buy Rating With Promising Fiscal Projections and Undervalued Stock
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Crispr Therapeutics AG (CRSP) and Tango Therapeutics (TNGX)